Author/Authors :
Masmoudi، نويسنده , , Amine and Toumi، نويسنده , , Nabil and Khanfir، نويسنده , , Afef and Kallel-Slimi، نويسنده , , Lamia and Daoud، نويسنده , , Jamel and Karray، نويسنده , , Hela and Frikha، نويسنده , , Mounir، نويسنده ,
Abstract :
Summary
n-Barr virus (EBV) is constantly present in undifferentiated and poorly-differentiated nasopharyngeal cancer. Thus, tumour-associated viral antigens are potential targets for immunotherapy. Recently, both preclinical and early clinical studies have shown that various strategies can enhance EBV-specific immunity. Moreover, significant anti-tumour effect has been observed, and was generally correlated with biological response. The present review discusses the rational for EBV-targeted immunotherapy and summarises the latest developments in this area.
Keywords :
Nasopharyngeal cancer , Vaccination , Epstein-Barr virus , adoptive immunotherapy
